Access the full text.
Sign up today, get DeepDyve free for 14 days.
Nathan West, K. Milne, P. Truong, N. Macpherson, B. Nelson, P. Watson (2011)
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancerBreast Cancer Research : BCR, 13
K. Bauer, Monica Brown, R. Cress, C. Parise, V. Caggiano (2007)
Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 109
J. Fricker (2009)
San Antonio Breast Cancer Symposium.The Lancet. Oncology, 10 1
C. Shapiro, L. Cascione, P. Gasparini, F. Lovat, Stefania Carasi, A. Pulvirenti, A. Ferro, K. Huebner (2012)
Use of microRNA (miR) expression profiling to identify distinct subclasses of triple-negative breast cancers (TNBC).Journal of Clinical Oncology, 30
P. Tassone, P. Tassone, P. Tagliaferri, A. Perricelli, S. Blotta, B. Quaresima, Marialuisa Martelli, A. Goel, V. Barbieri, F. Costanzo, C. Boland, S. Venuta (2003)
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of Cancer, 88
S. Isakoff, B. Overmoyer, N. Tung, R. Gelman, V. Giranda, K. Bernhard, K. Habin, L. Ellisen, E. Winer, P. Goss (2010)
A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.Journal of Clinical Oncology, 28
S. Irshad, P. Ellis, A. Tutt (2011)
Molecular heterogeneity of triple-negative breast cancer and its clinical implicationsCurrent Opinion in Oncology, 23
R. Finn, C. Bengala, N. Ibrahim, L. Strauss, J. Fairchild, O. Sy, H. Roché, J. Sparano, L. Goldstein (2009)
Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059.Cancer Research, 69
Katrina Trivers, M. Lund, P. Porter, J. Liff, E. Flagg, E. Flagg, R. Coates, J. Eley (2009)
The epidemiology of triple-negative breast cancer, including raceCancer Causes & Control, 20
G. Minckwitz, W. Jonat, P. Fasching, A. Bois, U. Kleeberg, H. Lück, E. Kettner, J. Hilfrich, W. Eiermann, J. Torode, A. Schneeweiss (2004)
A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancerBreast Cancer Research and Treatment, 89
F. Huang, K. Reeves, Xia Han, C. Fairchild, S. Platero, T. Wong, F. Lee, P. Shaw, E. Clark (2007)
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.Cancer research, 67 5
H. Bear, G. Tang, P. Rastogi, C. Geyer, A. Robidoux, J. Atkins, Luis Baez-Diaz, A. Brufsky, R. Mehta, L. Fehrenbacher, J. Young, F. Senecal, R. Gaur, R. Margolese, P. Adams, H. Gross, J. Costantino, S. Swain, E. Mamounas, N. Wolmark (2012)
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.The New England journal of medicine, 366 4
J. O’Shaughnessy, V. Diéras, J. Glaspy, A. Brufsky, K. Miller, D. Miles, P. Koralewski, S. Phan, S. Bhattacharya (2009)
Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC).Cancer Research, 69
J. Ji, M. Lee, M. Kadota, Yiping Zhang, R. Parchment, J. Tomaszewski, J. Doroshow (2011)
Abstract 4527: Pharmacodynamic and pathway analysis of three presumed inhibitors of poly (ADP-ribose) polymerase: ABT-888, AZD2281, and BSI201Cancer Research, 71
H. Burstein, A. Elias, H. Rugo, M. Cobleigh, A. Wolff, P. Eisenberg, M. Lehman, B. Adams, C. Bello, S. Deprimo, C. Baum, K. Miller (2008)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 11
B. Lehmann, Joshua Bauer, X. Chen, M. Sanders, A. Chakravarthy, Y. Shyr, J. Pietenpol (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.The Journal of clinical investigation, 121 7
M. Graeser, Afshan Mccarthy, C. Lord, K. Savage, M. Hills, J. Salter, N. Orr, M. Parton, I. Smith, J. Reis-Filho, M. Dowsett, A. Ashworth, N. Turner (2010)
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast CancerClinical Cancer Research, 16
K. Amirikia, P. Mills, J. Bush, L. Newman (2011)
Higher population‐based incidence rates of triple‐negative breast cancer among young African‐American womenCancer, 117
A. González-Angulo, K. Timms, Shuying Liu, Huiqin Chen, J. Litton, J. Potter, J. Lanchbury, K. Stemke‐Hale, B. Hennessy, B. Arun, G. Hortobagyi, K. Do, G. Mills, F. Meric-Bernstam (2011)
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast CancerClinical Cancer Research, 17
G. Minckwitz, M. Untch, J. Blohmer, S. Costa, H. Eidtmann, P. Fasching, B. Gerber, W. Eiermann, J. Hilfrich, J. Huober, C. Jackisch, M. Kaufmann, G. Konecny, C. Denkert, V. Nekljudova, K. Mehta, S. Loibl (2012)
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 15
J. Baselga, S. Stemmer, A. Pêgo, A. Chan, J. Goeminne, M. Graas, J. Kennedy, E. Gil, A. Zubel, J. Groos, U. Kia, A. Schneeweiss (2010)
Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 TrialCancer Research, 70
R. Dent, G. Lindeman, M. Clemons, H. Wildiers, A. Chan, N. Mccarthy, C. Singer, E. Lowe, K. Kemsley, J. Carmichael (2010)
Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.Journal of Clinical Oncology, 28
X. Chen, X. Chen, X. Nie, C. Chen, Junlong Wu, Junlong Wu, J. Wu, Jinsong Lu, Z-M Shao, Z. Shen, K. Shen, K. Shen (2010)
Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 21 5
I. Mayer, H. Burris, J. Bendell, J. Means-Powell, C. Arteaga, Y. Shyr, J. Pietenpol (2009)
A Phase Ib Trial of RAD001, an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer.Cancer Research, 69
Linda Degraffenried, L. Fulcher, W. Friedrichs, Viktor Grünwald, Ratna Ray, Manuel Hidalgo (2004)
Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.Annals of oncology : official journal of the European Society for Medical Oncology, 15 10
W. Sikov, D. Dizon, R. Strenger, R. Legare, K. Theall, T. Graves, J. Gass, T. Kennedy, M. Fenton (2009)
Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 28
Patricia Keller, Lisa Arendt, Adam Skibinski, T. Logvinenko, I. Klebba, Shumin Dong, Avi Smith, A. Prat, C. Perou, Hannah Gilmore, S. Schnitt, S. Naber, J. Garlick, C. Kuperwasser (2011)
Defining the cellular precursors to human breast cancerProceedings of the National Academy of Sciences, 109
Michael Green, P. Francis, V. Gebski, Vernon Harvey, Chris Karapetis, Arlene Chan, Raymond Snyder, A. Fong, R. Basser, John Forbes (2009)
Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 20 11
E. Gutteridge, A. Agrawal, R. Nicholson, K. Cheung, J. Robertson, J. Gee (2010)
The effects of gefitinib in tamoxifen‐resistant and hormone‐insensitive breast cancer: A phase II studyInternational Journal of Cancer, 126
G. Minckwitz, H. Eidtmann, M. Rezai, P. Fasching, H. Tesch, H. Eggemann, I. Schrader, K. Kittel, C. Hanusch, R. Kreienberg, C. Solbach, B. Gerber, C. Jackisch, G. Kunz, J. Blohmer, J. Huober, M. Hauschild, T. Fehm, B. Müller, C. Denkert, S. Loibl, V. Nekljudova, M. Untch (2012)
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.The New England journal of medicine, 366 4
Hyewon Lee, S. Jung, J. Ro, Youngmee Kwon, J. Sohn, I. Park, K. Lee, Seeyoun Lee, S. Kim, H. Kang, K. Ko, J. Ro (2012)
Metaplastic breast cancer: clinicopathological features and its prognosisJournal of Clinical Pathology, 65
Cynthia Ma, S. Cai, Shunqiang Li, C. Ryan, Zhanfang Guo, W. Schaiff, Li Lin, J. Hoog, Reece Goiffon, A. Prat, R. Aft, M. Ellis, H. Piwnica-Worms (2012)
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.The Journal of clinical investigation, 122 4
L. Carey, E. Dees, L. Sawyer, Lisa Gatti, D. Moore, F. Collichio, D. Ollila, Carolyn Sartor, M. Graham, C. Perou (2007)
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 13
E. Lips, L. Mulder, Juliane Hannemann, N. Laddach, M. Peeters, M. Vijver, J. Wesseling, P. Nederlof, Sjoerd Rodenhuis (2011)
Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.Annals of oncology : official journal of the European Society for Medical Oncology, 22 4
K. Hoadley, V. Weigman, C. Fan, L. Sawyer, Xiaping He, M. Troester, Carolyn Sartor, Thais Rieger-House, P. Bernard, L. Carey, C. Perou (2007)
EGFR associated expression profiles vary with breast tumor subtypeBMC Genomics, 8
R. Finn, J. Dering, C. Ginther, Cindy Wilson, Padraic Glaspy, N. Tchekmedyian, D. Slamon (2007)
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitroBreast Cancer Research and Treatment, 105
W. Foulkes, I. Smith, J. Reis-Filho (2010)
Triple-negative breast cancer.The New England journal of medicine, 363 20
T. Sørlie, Yulei Wang, Chunlin Xiao, H. Johnsen, B. Naume, R. Samaha, A. Børresen-Dale (2006)
Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platformsBMC Genomics, 7
(2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancerBreast Cancer Research : BCR, 12
A. Prat, C. Perou (2010)
Deconstructing the molecular portraits of breast cancerMolecular Oncology, 5
G. Minckwitz, B. Müller, S. Loibl, J. Budczies, C. Hanusch, S. Darb-Esfahani, J. Hilfrich, E. Weiss, J. Huober, J. Blohmer, A. Bois, D. Zahm, F. Khandan, G. Hoffmann, B. Gerber, H. Eidtmann, F. Fend, M. Dietel, K. Mehta, C. Denkert (2011)
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 16
T. Byrski, R. Dent, P. Blecharz, M. Foszczyńska‐Kłoda, J. Gronwald, T. Huzarski, C. Cybulski, E. Marczyk, R. Chrzan, A. Eisen, J. Lubiński, S. Narod (2012)
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancerBreast Cancer Research : BCR, 14
J. Glendenning, A. Tutt (2011)
PARP inhibitors--current status and the walk towards early breast cancer.Breast, 20 Suppl 3
R. Millikan, B. Newman, C. Tse, P. Moorman, K. Conway, L. Dressler, Lisa Smith, M. Labbok, J. Geradts, J. Bensen, S. Jackson, S. Nyante, C. Livasy, L. Carey, H. Earp, C. Perou (2008)
Epidemiology of basal-like breast cancerBreast Cancer Research and Treatment, 109
W. Eiermann, Jonas Bergh, Jonas Bergh, Fatima Cardoso, Pierfranco Conte, J. Crown, Nicola Curtin, J. Gligorov, Barry Gusterson, H. Joensuu, B. Linderholm, Miguel Martin, F. Penault-Llorca, Bernhard Pestalozzi, Evangelia Razis, Christos Sotiriou, Sergei Tjulandin, Giuseppe Viale (2012)
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.Breast, 21 1
L. Carey, H. Rugo, P. Marcom, W. Irvin, M. Ferraro, E. Burrows, Xiaping He, C. Perou, E. Winer (2008)
TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancerJournal of Clinical Oncology, 26
C. Liedtke, C. Mazouni, K. Hess, F. André, A. Tordai, J. Mejia, W. Symmans, A. González-Angulo, B. Hennessy, Marjorie Green, M. Cristofanilli, G. Hortobagyi, L. Pusztai (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 8
Jos Hage, Cornelis Velde, Sven Mieog (2007)
Preoperative chemotherapy for women with operable breast cancer.The Cochrane database of systematic reviews, 2
M. Cheang, Miguel Martín, Torsten Nielsen, A. Prat, Á. Rodríguez-Lescure, A. Ruíz, Stephen Chia, Lois Shepherd, D. Voduc, P. Bernard, Matthew Ellis, C. Perou, A. Leo, Lisa Carey (2012)
Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG.Journal of Clinical Oncology, 30
H. Wildiers, C. Fontaine, P. Vuylsteke, M. Martens, J. Canon, W. Wynendaele, C. Focan, J. Degreve, R. Paridaens (2009)
SUCON Trial (SUnitinib CONsolidation Therapy in Metastatic Breast Cancer): A Belgian Multicenter Phase II Randomized Trial in Her2 Negative Metastatic Breast Cancer Evaluating Consolidation Antiangiogenic Therapy with Sunitinib after Objective Response to Taxane Chemotherapy.Cancer Research, 69
Tatiana Prowell, R. Pazdur (2012)
Pathological complete response and accelerated drug approval in early breast cancer.The New England journal of medicine, 366 26
J. O’Shaughnessy, C. Osborne, J. Pippen, M. Yoffe, D. Patt, C. Rocha, I. Koo, B. Sherman, C. Bradley (2011)
Iniparib plus chemotherapy in metastatic triple-negative breast cancer.The New England journal of medicine, 364 3
K. Miller, M. Estes, S. Perkins, B. Schneider, D. Matei, A. Storniolo, D. Ingram, M. Yoder, K. Kern, G. Sledge (2009)
An Exploratory Study of the Biological Activity of Sunitinib as a Component of Neoadjuvant Therapy for Breast Cancer.Cancer Research, 69
R. Finn (2008)
Targeting Src in breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 19 8
K. Stemke‐Hale, A. González-Angulo, A. Lluch, R. Neve, W. Kuo, M. Davies, M. Carey, Zhi Hu, Y. Guan, A. Sahin, W. Symmans, L. Pusztai, L. Nolden, H. Horlings, K. Berns, M. Hung, M. Vijver, V. Valero, J. Gray, R. Bernards, G. Mills, B. Hennessy (2008)
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.Cancer research, 68 15
M. Hammond, Daniel Hayes, M. Dowsett, D. Allred, K. Hagerty, S. Badve, P. Fitzgibbons, G. Francis, Neil Goldstein, M. Hayes, David Hicks, S. Lester, R. Love, P. Mangu, L. McShane, K. Miller, C. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, Jared Schwartz, F. Sweep, S. Taube, E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R. Williams, J. Wittliff, Antonio Wolff (2010)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.Archives of pathology & laboratory medicine, 134 6
A. Tutt, Mark Robson, J. Garber, S. Domchek, M. Audeh, J. Weitzel, M. Friedlander, J. Carmichael (2009)
Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 18_suppl
J. Bergh, R. Greil, N. Voytko, A. Makhson, J. Cortés, A. Lortholary, X. Huang, C. Giorgetti, K. Kern, M. Lichinitser (2010)
Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 18_suppl
D. Berry, C. Cirrincione, I. Henderson, M. Citron, D. Budman, L. Goldstein, S. Martino, E. Perez, H. Muss, L. Norton, C. Hudis, Eric Winer (2006)
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancerJAMA, 295
A. Gonçalves, P. Finetti, R. Sabatier, M. Gilabert, J. Adélaide, J. Borg, M. Chaffanet, P. Viens, D. Birnbaum, F. Bertucci (2011)
Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysisBreast Cancer Research and Treatment, 127
Helena Chang, J. Glaspy, M. Allison, F. Kass, R. Elashoff, D. Chung, J. Gornbein (2010)
Differential response of triple‐negative breast cancer to a docetaxel and carboplatin‐based neoadjuvant treatmentCancer, 116
M. Dickler, M. Cobleigh, K. Miller, P. Klein, E. Winer (2009)
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancerBreast Cancer Research and Treatment, 115
KR Bauer, M Brown, RD Cress, CA Parise, V Caggiano (2007)
Descriptive analysis of estrogen receptor-negative, progesterone receptor-negative and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer RegistryCancer., 109
L. Esserman, D. Berry, A. DeMichele, L. Carey, S. Davis, M. Buxton, C. Hudis, J. Gray, C. Perou, C. Yau, C. Livasy, H. Krontiras, L. Montgomery, D. Tripathy, C. Lehman, Minetta Liu, O. Olopade, H. Rugo, J. Carpenter, L. Dressler, D. Chhieng, Baljit Singh, C. Mies, J. Rabban, Yunni-Yi Chen, D. Giri, L. Veer, N. Hylton (2012)
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 26
T. Grushko, Chika Nwachukwu, S. Charoenthammaraksa, D. Huo, A. Khramtsov, H. Mashek, Chunling Zhang, Jinhua Xu, C. Perou, O. Olopade (2010)
Evaluation of BRCA1 inactivation by promoter methylation as a marker of triple-negative and basal-like breast cancers.Journal of Clinical Oncology, 28
B. Marty, V. Maire, E. Gravier, G. Rigaill, A. Vincent-Salomon, Marion Kappler, I. Lebigot, Fathia Djelti, Audrey Tourdès, P. Gestraud, P. Hupé, E. Barillot, F. Cruzalegui, G. Tucker, M. Stern, J. Thiery, J. Hickman, T. Dubois (2008)
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cellsBreast Cancer Research : BCR, 10
T. Karn, L. Pusztai, U. Holtrich, T. Iwamoto, Christine Shiang, Marcus Schmidt, V. Müller, C. Solbach, R. Gaetje, L. Hanker, A. Ahr, C. Liedtke, E. Ruckhäberle, M. Kaufmann, A. Rody (2011)
Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive SignaturesPLoS ONE, 6
D. Silver, A. Richardson, A. Eklund, Z. Wang, Z. Szallasi, Qiyuan Li, N. Juul, C. Leong, Diana Calogrias, Ayodele Buraimoh, Aquila Fatima, R. Gelman, P. Ryan, N. Tung, A. Nicolo, S. Ganesan, A. Miron, C. Colín, D. Sgroi, L. Ellisen, E. Winer, J. Garber (2010)
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 7
T. Byrski, T. Huzarski, R. Dent, J. Gronwald, D. Zuziak, C. Cybulski, J. Kładny, B. Górski, J. Lubiński, S. Narod (2009)
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patientsBreast Cancer Research and Treatment, 115
E. Rakha, J. Reis-Filho, I. Ellis (2008)
Basal-like breast cancer: a critical review.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 15
R. Rouzier, C. Perou, W. Symmans, N. Ibrahim, M. Cristofanilli, K. Anderson, K. Hess, J. Stec, J. Stec, M. Ayers, P. Wagner, P. Morandi, Chang Fan, Islam Rabiul, J. Ross, G. Hortobagyi, L. Pusztai (2005)
Breast Cancer Molecular Subtypes Respond Differently to Preoperative ChemotherapyClinical Cancer Research, 11
J. O’Shaughnessy, L. Schwartzberg, M. Danso, H. Rugo, K. Miller, D. Yardley, Robert Carlson, R. Finn, Eric Charpentier, M. Freese, Sanjay Gupta, A. Blackwood-Chirchir, Eric Winer (2011)
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
N. Turner, A. Tutt, A. Ashworth (2004)
Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 4
G. Curigliano (2011)
Immunity and autoimmunity: revising the concepts of response to breast cancer.Breast, 20 Suppl 3
K. Reeder-Hayes, L. Carey, W. Sikov (2010)
Clinical trials in triple negative breast cancer.Breast disease, 32 1-2
P. Rastogi, S. Anderson, H. Bear, C. Geyer, M. Kahlenberg, A. Robidoux, R. Margolese, J. Hoehn, V. Vogel, S. Dakhil, D. Tamkus, K. King, E. Pajon, Mary Wright, J. Robert, S. Paik, E. Mamounas, N. Wolmark (2008)
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 5
J. Crown, V. Diéras, E. Starosławska, D. Yardley, N. Davidson, T. Bachelot, V. Tassell, X. Huang, K. Kern, G. Romieu (2010)
Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 18_suppl
Z. Nahleh (2010)
Neoadjuvant chemotherapy for “Triple Negative” breast cancer: a review of current practice and future outlookMedical Oncology, 27
B. Linderholm, H. Hellborg, U. Johansson, G. Elmberger, L. Skoog, J. Lehtiö, R. Lewensohn (2009)
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 20 10
W. Kaelin (2005)
The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 5
C. Fisher, Cynthia Ma, W. Gillanders, R. Aft, T. Eberlein, F. Gao, J. Margenthaler (2011)
Neoadjuvant Chemotherapy Is Associated with Improved Survival Compared with Adjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer Only after Complete Pathologic ResponseAnnals of Surgical Oncology, 19
M. Vollebergh, E. Lips, P. Nederlof, L. Wessels, L. Wessels, M. Schmidt, E. Beers, S. Cornelissen, M. Holtkamp, F. Froklage, de Vries, J. Schrama, J. Wesseling, M. Vijver, H. Tinteren, M. Bruin, Michael Hauptmann, S. Rodenhuis, Sabine Linn (2010)
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patientsAnnals of Oncology, 22
With the help of ever more powerful research tools triple-negative breast cancer (TNBC) is slowly yielding its secrets. The neoadjuvant setting gives us the best opportunity to address questions raised by the biologic heterogeneity of the disease, and eventually design individualized treatment plans for patients who are identified as likely to have a suboptimal response to chemotherapy. However, given a plethora of aberrantly activated pathways, exacerbated by its genomic instability, the challenge is to separate what drives the behavior of TNBC from the consequences of that behavior. This article reviews our current understanding of TNBC, including recent efforts to identify clinically relevant subsets of the disease, the role of treatments that exploit defects in DNA repair, including chemotherapeutic agents such as the platinum analogues, and biologic agents such as the poly ADP-ribose polymerases (PARP) inhibitors, and then discusses potential targeted approaches to its treatment, most of which are still early in development.
Current Breast Cancer Reports – Springer Journals
Published: Sep 20, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.